Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IMGN |
---|---|---|
09:32 ET | 57529 | 3.5 |
09:34 ET | 10271 | 3.48 |
09:36 ET | 11872 | 3.47 |
09:38 ET | 3081 | 3.46 |
09:39 ET | 4400 | 3.43 |
09:41 ET | 2391 | 3.435 |
09:43 ET | 11870 | 3.435 |
09:45 ET | 5307 | 3.42 |
09:48 ET | 3630 | 3.4 |
09:50 ET | 34110 | 3.41 |
09:52 ET | 143119 | 3.45 |
09:54 ET | 13363 | 3.435 |
09:56 ET | 3200 | 3.435 |
09:57 ET | 5885 | 3.445 |
09:59 ET | 3700 | 3.43 |
10:01 ET | 25082 | 3.42 |
10:03 ET | 8471 | 3.44 |
10:06 ET | 4724 | 3.44 |
10:08 ET | 13399 | 3.435 |
10:10 ET | 19685 | 3.42 |
10:12 ET | 10178 | 3.425 |
10:14 ET | 8176 | 3.445 |
10:15 ET | 16653 | 3.425 |
10:17 ET | 5312 | 3.445 |
10:19 ET | 51077 | 3.45 |
10:21 ET | 34401 | 3.48 |
10:24 ET | 20108 | 3.485 |
10:26 ET | 6068 | 3.49 |
10:28 ET | 45792 | 3.5 |
10:30 ET | 25104 | 3.5 |
10:32 ET | 11293 | 3.515 |
10:33 ET | 29794 | 3.52 |
10:35 ET | 15866 | 3.515 |
10:37 ET | 14049 | 3.525 |
10:39 ET | 25751 | 3.535 |
10:42 ET | 25892 | 3.5278 |
10:44 ET | 6787 | 3.54 |
10:46 ET | 10450 | 3.525 |
10:48 ET | 11737 | 3.535 |
10:50 ET | 18773 | 3.49 |
10:51 ET | 9914 | 3.495 |
10:53 ET | 17767 | 3.505 |
10:55 ET | 20248 | 3.51 |
10:57 ET | 8933 | 3.51 |
11:00 ET | 900 | 3.52 |
11:02 ET | 18054 | 3.51 |
11:04 ET | 5768 | 3.51 |
11:06 ET | 4009 | 3.51 |
11:08 ET | 2923 | 3.51 |
11:09 ET | 8986 | 3.53 |
11:11 ET | 2800 | 3.53 |
11:13 ET | 22484 | 3.5235 |
11:15 ET | 400 | 3.53 |
11:18 ET | 20514 | 3.53 |
11:20 ET | 19280 | 3.52 |
11:22 ET | 17170 | 3.52 |
11:24 ET | 12359 | 3.52 |
11:26 ET | 6613 | 3.535 |
11:27 ET | 500 | 3.54 |
11:29 ET | 5494 | 3.54 |
11:31 ET | 14097 | 3.545 |
11:33 ET | 1303 | 3.55 |
11:36 ET | 31130 | 3.54 |
11:38 ET | 1453 | 3.535 |
11:40 ET | 3000 | 3.545 |
11:42 ET | 12090 | 3.555 |
11:44 ET | 30419 | 3.555 |
11:45 ET | 14627 | 3.565 |
11:47 ET | 6652 | 3.57 |
11:49 ET | 10860 | 3.575 |
11:51 ET | 5783 | 3.57 |
11:54 ET | 5491 | 3.565 |
11:56 ET | 400 | 3.565 |
11:58 ET | 17356 | 3.57 |
12:00 ET | 4733 | 3.58 |
12:02 ET | 11305 | 3.575 |
12:03 ET | 10413 | 3.565 |
12:05 ET | 4322 | 3.57 |
12:07 ET | 9836 | 3.57 |
12:09 ET | 8458 | 3.58 |
12:12 ET | 4824 | 3.58 |
12:14 ET | 300 | 3.58 |
12:16 ET | 3884 | 3.59 |
12:18 ET | 10757 | 3.575 |
12:20 ET | 800 | 3.575 |
12:21 ET | 9817 | 3.575 |
12:23 ET | 7780 | 3.56 |
12:25 ET | 4208 | 3.565 |
12:27 ET | 17447 | 3.56 |
12:30 ET | 10601 | 3.55 |
12:32 ET | 58540 | 3.52 |
12:34 ET | 11720 | 3.52 |
12:36 ET | 7584 | 3.505 |
12:38 ET | 14861 | 3.51 |
12:39 ET | 8021 | 3.51 |
12:41 ET | 3985 | 3.52 |
12:43 ET | 4038 | 3.525 |
12:45 ET | 1100 | 3.53 |
12:48 ET | 1355 | 3.53 |
12:50 ET | 15324 | 3.52 |
12:52 ET | 3050 | 3.525 |
12:54 ET | 8726 | 3.525 |
12:56 ET | 1730 | 3.535 |
12:57 ET | 4906 | 3.54 |
12:59 ET | 28775 | 3.55 |
01:01 ET | 10063 | 3.53 |
01:03 ET | 13898 | 3.525 |
01:06 ET | 529 | 3.53 |
01:08 ET | 6306 | 3.53 |
01:10 ET | 9200 | 3.52 |
01:12 ET | 556 | 3.52 |
01:14 ET | 800 | 3.52 |
01:15 ET | 6787 | 3.505 |
01:17 ET | 4087 | 3.51 |
01:19 ET | 11968 | 3.505 |
01:21 ET | 8545 | 3.5 |
01:24 ET | 10809 | 3.505 |
01:26 ET | 4016 | 3.5 |
01:28 ET | 2300 | 3.505 |
01:30 ET | 5907 | 3.52 |
01:32 ET | 5118 | 3.52 |
01:33 ET | 4315 | 3.505 |
01:35 ET | 1718 | 3.52 |
01:37 ET | 800 | 3.52 |
01:39 ET | 3000 | 3.53 |
01:42 ET | 5586 | 3.54 |
01:44 ET | 28485 | 3.545 |
01:46 ET | 13985 | 3.55 |
01:48 ET | 7312 | 3.545 |
01:50 ET | 2800 | 3.55 |
01:51 ET | 16840 | 3.555 |
01:53 ET | 3700 | 3.56 |
01:55 ET | 11138 | 3.555 |
01:57 ET | 15856 | 3.545 |
02:00 ET | 800 | 3.545 |
02:02 ET | 4933 | 3.54 |
02:04 ET | 78356 | 3.545 |
02:06 ET | 1200 | 3.545 |
02:08 ET | 800 | 3.545 |
02:09 ET | 25140 | 3.56 |
02:11 ET | 2562 | 3.57 |
02:13 ET | 2500 | 3.565 |
02:15 ET | 22294 | 3.565 |
02:18 ET | 2100 | 3.565 |
02:20 ET | 5885 | 3.5544 |
02:22 ET | 11336 | 3.56 |
02:24 ET | 2529 | 3.565 |
02:26 ET | 3309 | 3.57 |
02:27 ET | 14616 | 3.575 |
02:29 ET | 3481 | 3.575 |
02:31 ET | 3226 | 3.575 |
02:33 ET | 2410 | 3.58 |
02:36 ET | 2558 | 3.58 |
02:38 ET | 15498 | 3.585 |
02:40 ET | 42461 | 3.595 |
02:42 ET | 36759 | 3.585 |
02:44 ET | 6683 | 3.575 |
02:45 ET | 18845 | 3.565 |
02:47 ET | 6841 | 3.555 |
02:49 ET | 18147 | 3.55 |
02:51 ET | 1548 | 3.545 |
02:54 ET | 1000 | 3.545 |
02:56 ET | 11022 | 3.535 |
02:58 ET | 14732 | 3.535 |
03:00 ET | 14350 | 3.53 |
03:02 ET | 9426 | 3.535 |
03:03 ET | 8900 | 3.535 |
03:05 ET | 5929 | 3.535 |
03:07 ET | 6544 | 3.53 |
03:09 ET | 6600 | 3.515 |
03:12 ET | 8819 | 3.525 |
03:14 ET | 6954 | 3.515 |
03:16 ET | 6174 | 3.515 |
03:18 ET | 3900 | 3.515 |
03:20 ET | 1500 | 3.515 |
03:21 ET | 25981 | 3.505 |
03:23 ET | 10444 | 3.515 |
03:25 ET | 1923 | 3.515 |
03:27 ET | 3957 | 3.515 |
03:30 ET | 19136 | 3.52 |
03:32 ET | 10858 | 3.52 |
03:34 ET | 5715 | 3.53 |
03:36 ET | 8077 | 3.54 |
03:38 ET | 6362 | 3.55 |
03:39 ET | 18198 | 3.565 |
03:41 ET | 24058 | 3.56 |
03:43 ET | 6949 | 3.56 |
03:45 ET | 28806 | 3.565 |
03:48 ET | 10750 | 3.55 |
03:50 ET | 32069 | 3.545 |
03:52 ET | 32166 | 3.55 |
03:54 ET | 39744 | 3.545 |
03:56 ET | 34672 | 3.54 |
03:57 ET | 61235 | 3.54 |
03:59 ET | 682584 | 3.54 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ImmunoGen Inc | 780.7M | -5.9x | --- |
Kymera Therapeutics Inc | 733.4M | -5.7x | --- |
Avid Bioservices Inc | 764.4M | 81.5x | --- |
Chinook Therapeutics Inc | 833.7M | -7.4x | --- |
Enanta Pharmaceuticals Inc | 812.6M | -7.1x | --- |
Deciphera Pharmaceuticals Inc | 712.5M | -2.2x | --- |
ImmunoGen, Inc. is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine (IMGN853), IMGN632, MGC936 and IMGN151. Mirvetuximab soravtansine is a first-in-class ADC targeting folate receptor alpha (FRα), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. IMGN632 (Pivekimab sunirine) is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. It is advancing pivekimab in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $780.7M |
---|---|
Revenue (TTM) | $92.2M |
Shares Outstanding | 220.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-0.60 |
Book Value | $1.48 |
P/E Ratio | -5.9x |
Price/Sales (TTM) | 8.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -129.04% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.